Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Company has announced that its subsidiary in China, Daiichi Pharmaceutical Co, has filed an application for KMD-3213 to China's State Food and Drug Administration. The drug was developed for treatment of dysuria associated with benign prostatic hyperplasia.
Subscribe to our email newsletter
KMD-3213 is a selective alpha 1A-adrenoceptor antagonist originally discovered by Kissei Pharmaceutical Co. It was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief in Japan.
KMD-3213 has shown efficacy in significantly improving urinary disturbance soon after dosage and is expected to contribute to improving the quality of life in patients.